CO2021008187A2 - Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica - Google Patents

Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica

Info

Publication number
CO2021008187A2
CO2021008187A2 CONC2021/0008187A CO2021008187A CO2021008187A2 CO 2021008187 A2 CO2021008187 A2 CO 2021008187A2 CO 2021008187 A CO2021008187 A CO 2021008187A CO 2021008187 A2 CO2021008187 A2 CO 2021008187A2
Authority
CO
Colombia
Prior art keywords
lateral sclerosis
amyotrophic lateral
compositions
treating
methods
Prior art date
Application number
CONC2021/0008187A
Other languages
English (en)
Inventor
Ivan Alexandrov Nestorov
Toby Ferguson
Daniel A Norris
Original Assignee
Biogen Ma Inc
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Ionis Pharmaceuticals Inc filed Critical Biogen Ma Inc
Publication of CO2021008187A2 publication Critical patent/CO2021008187A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan pautas posológicas para oligonucleótidos antisentido que se dirigen a SOD1 y sales de estos. Las pautas posológicas se utilizan en el tratamiento de sujetos que tienen o se encuentran en riesgo de desarrollar esclerosis lateral amiotrófica.
CONC2021/0008187A 2018-12-14 2021-06-23 Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica CO2021008187A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862779916P 2018-12-14 2018-12-14
US201962807603P 2019-02-19 2019-02-19
US201962840879P 2019-04-30 2019-04-30
PCT/US2019/065936 WO2020123783A1 (en) 2018-12-14 2019-12-12 Compositions and methods for treating and preventing amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CO2021008187A2 true CO2021008187A2 (es) 2021-09-09

Family

ID=69160351

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008187A CO2021008187A2 (es) 2018-12-14 2021-06-23 Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica

Country Status (19)

Country Link
US (1) US20220073930A1 (es)
EP (1) EP3894557A1 (es)
JP (1) JP2022513597A (es)
KR (1) KR20210131992A (es)
CN (1) CN113330116A (es)
AU (1) AU2019396522A1 (es)
BR (1) BR112021011334A2 (es)
CA (1) CA3115549A1 (es)
CL (1) CL2021001136A1 (es)
CO (1) CO2021008187A2 (es)
CR (1) CR20210384A (es)
IL (1) IL283833A (es)
JO (1) JOP20210143A1 (es)
MX (1) MX2021005086A (es)
PH (1) PH12021551365A1 (es)
SG (1) SG11202103415WA (es)
TW (1) TW202035694A (es)
UY (1) UY38506A (es)
WO (1) WO2020123783A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3743728A1 (en) 2018-01-25 2020-12-02 Biogen MA Inc. Methods of treating spinal muscular atrophy
WO2022212459A1 (en) * 2021-03-31 2022-10-06 Biogen Ma Inc. Treatment of amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
WO2013134403A1 (en) * 2012-03-06 2013-09-12 The Washington University Method of treating neurodegenerative diseases with microrna regulators
RU2019130898A (ru) * 2014-03-19 2019-11-11 Ионис Фармасьютикалз, Инк. Композиции для модуляции экспрессии атаксина 2
US10385341B2 (en) * 2014-04-01 2019-08-20 Biogen Ma Inc. Compositions for modulating SOD-1 expression
AU2018261790A1 (en) * 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US20210172963A1 (en) * 2017-05-26 2021-06-10 University Of Miami Determining onset of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
UY38506A (es) 2020-06-30
WO2020123783A1 (en) 2020-06-18
EP3894557A1 (en) 2021-10-20
JOP20210143A1 (ar) 2023-01-30
CA3115549A1 (en) 2020-06-18
US20220073930A1 (en) 2022-03-10
TW202035694A (zh) 2020-10-01
CN113330116A (zh) 2021-08-31
PH12021551365A1 (en) 2021-11-22
CL2021001136A1 (es) 2022-01-14
JP2022513597A (ja) 2022-02-09
IL283833A (en) 2021-07-29
MX2021005086A (es) 2021-08-16
SG11202103415WA (en) 2021-06-29
KR20210131992A (ko) 2021-11-03
AU2019396522A1 (en) 2021-05-06
BR112021011334A2 (pt) 2021-09-08
CR20210384A (es) 2021-12-20

Similar Documents

Publication Publication Date Title
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
CO2021008187A2 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
CO2021009163A2 (es) Composiciones de agente de arni de proteína precursora de amiloide (app) y método de uso de las mismas
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
CL2019001415A1 (es) Composición para promover la diferenciación de y para proteger las células madre neuronales y método para inducir la regeneración neural utilizando la misma.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CO2016000671A1 (es) Construcciones de variantes de sirp-alfa y sus usos
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2019002245A2 (es) Combinación de agonistas de fxr
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
CY1126041T1 (el) Σκευασμα φαρμακου για χρηση στον αποτελεσματικο ελεγχο οξεος ή/και χρονιου πονου
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
CO2022000270A2 (es) Inhibidores de enzimas
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
AR117329A1 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
BR112019008787A2 (pt) combinações de inibidores de fgfr4 e sequestrantes de ácido biliar